Dr. Aggarwal on NGS in Molecular Testing in NSCLC

Supplements And Featured Publications, 2021 Year in Review: Updates in Biomarker-Driven Lung Cancer, Volume 1, Issue 1

Charu Aggarwal, MD, MPH, discusses the optimal use of next-generation sequencing in molecular testing in non­–small cell lung cancer.

Charu Aggarwal, MD, MPH, Leslye M. Heisler associate professor for lung cancer excellence, Perelman School of Medicine, University of Pennsylvania, discusses the optimal use of next-generation sequencing in molecular testing in non­–small cell lung cancer (NSCLC).

Though tissue-based NGS remains the standard for molecular testing in NSCLC, tumors can now be sequenced through the minimally invasive plasma-based NGS, Aggarwal says. By utilizing both tissue-based and liquid-based NGS approaches, physicians can gain more from the testing, Aggarwal explains.

All patients with stage IV NSCLC, particularly those with a nonsquamous histology, must undergo NGS molecular testing, Aggarwal concludes.